Bridgebio Pharma Stock Analysis
| BBIO Stock | USD 75.85 0.60 0.80% |
IPO Date 27th of June 2019 | 200 Day MA 55.8651 | 50 Day MA 75.4248 | Beta 1.101 |
BridgeBio Pharma has over 1.73 Billion in debt which may indicate that it relies heavily on debt financing. At this time, BridgeBio Pharma's Long Term Debt Total is very stable compared to the past year. As of the 18th of February 2026, Short Term Debt is likely to grow to about 4.1 M, while Short and Long Term Debt Total is likely to drop about 1.1 B. With a high degree of financial leverage come high-interest payments, which usually reduce BridgeBio Pharma's Earnings Per Share (EPS).
Asset vs Debt
Equity vs Debt
BridgeBio Pharma's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. BridgeBio Pharma's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps BridgeBio Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect BridgeBio Pharma's stakeholders.
For many companies, including BridgeBio Pharma, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for BridgeBio Pharma, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, BridgeBio Pharma's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Price Book 123.6828 | Enterprise Value Ebitda (9.40) | Price Sales 40.7596 | Shares Float 151 M | Wall Street Target Price 98.3 |
BridgeBio Pharma is undervalued with Real Value of 86.14 and Target Price of 98.3. The main objective of BridgeBio Pharma stock analysis is to determine its intrinsic value, which is an estimate of what BridgeBio Pharma is worth, separate from its market price. There are two main types of BridgeBio Pharma's stock analysis: fundamental analysis and technical analysis.
The BridgeBio Pharma stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. BridgeBio Pharma is usually not traded on Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day ( substitute day ), Independence Day. BridgeBio Stock trading window is adjusted to America/New York timezone.
BridgeBio | Build AI portfolio with BridgeBio Stock |
BridgeBio Stock Analysis Notes
About 99.0% of the company shares are held by institutions such as insurance companies. The company has Price/Earnings To Growth (PEG) ratio of 0.05. BridgeBio Pharma recorded a loss per share of 4.21. The entity had not issued any dividends in recent years. BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company was founded in 2015 and is headquartered in Palo Alto, California. Bridgebio Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 576 people. For more info on BridgeBio Pharma please contact the company at 650 391 9740 or go to https://bridgebio.com.BridgeBio Pharma Investment Alerts
| BridgeBio Pharma had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 221.9 M. Net Loss for the year was (543.35 M) with profit before overhead, payroll, taxes, and interest of 338.84 M. | |
| BridgeBio Pharma currently holds about 715.71 M in cash with (520.73 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.83. | |
| Over 99.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from simplywall.st: Ionis Regulatory Wins Highlight Growing Rare Disease Revenue Potential |
BridgeBio Largest EPS Surprises
Earnings surprises can significantly impact BridgeBio Pharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2020-03-02 | 2019-12-31 | -0.7 | -0.62 | 0.08 | 11 | ||
2023-05-04 | 2023-03-31 | -0.83 | -0.92 | -0.09 | 10 | ||
2025-04-30 | 2025-03-31 | -0.89 | -0.9888 | -0.0988 | 11 |
BridgeBio Pharma Environmental, Social, and Governance (ESG) Scores
BridgeBio Pharma's ESG score is a quantitative measure that evaluates BridgeBio Pharma's performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of BridgeBio Pharma's operations that may have significant financial implications and affect BridgeBio Pharma's stock price as well as guide investors towards more socially responsible investments.
BridgeBio Stock Institutional Investors
| Shares | Amvescap Plc. | 2025-06-30 | 2.8 M | Goldman Sachs Group Inc | 2025-06-30 | 2.6 M | Alliancebernstein L.p. | 2025-06-30 | 2.5 M | Laurion Capital Management Lp | 2025-06-30 | 2.4 M | Two Sigma Investments Llc | 2025-06-30 | 2.3 M | Macquarie Group Ltd | 2025-06-30 | 2.1 M | D. E. Shaw & Co Lp | 2025-06-30 | 2.1 M | Fmr Inc | 2025-06-30 | 2 M | Norges Bank | 2025-06-30 | 2 M | Viking Global Investors Lp | 2025-06-30 | 18.6 M | Vanguard Group Inc | 2025-06-30 | 16.5 M |
BridgeBio Market Capitalization
The company currently falls under 'Large-Cap' category with a current market capitalization of 14.42 B.BridgeBio Profitablity
The company has Profit Margin (PM) of (2.25) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.13) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.13.| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.69) | (0.72) | |
| Return On Capital Employed | (0.89) | (0.94) | |
| Return On Assets | (0.67) | (0.70) | |
| Return On Equity | 0.33 | 0.34 |
Management Efficiency
BridgeBio Pharma has return on total asset (ROA) of (0.4348) % which means that it has lost $0.4348 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (17.8967) %, meaning that it created substantial loss on money invested by shareholders. BridgeBio Pharma's management efficiency ratios could be used to measure how well BridgeBio Pharma manages its routine affairs as well as how well it operates its assets and liabilities. As of the 18th of February 2026, Return On Equity is likely to grow to 0.34, while Return On Tangible Assets are likely to drop (0.72). At this time, BridgeBio Pharma's Non Current Assets Total are very stable compared to the past year. As of the 18th of February 2026, Other Assets is likely to grow to about 170 M, while Total Assets are likely to drop about 687.5 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (9.01) | (8.56) | |
| Tangible Book Value Per Share | (9.16) | (8.70) | |
| Enterprise Value Over EBITDA | (12.68) | (13.32) | |
| Price Book Value Ratio | (3.13) | (2.97) | |
| Enterprise Value Multiple | (12.68) | (13.32) | |
| Price Fair Value | (3.13) | (2.97) | |
| Enterprise Value | 7.1 B | 7.5 B |
The operational strategies employed by BridgeBio Pharma management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Technical Drivers
As of the 18th of February 2026, BridgeBio Pharma shows the Downside Deviation of 3.47, risk adjusted performance of 0.0723, and Mean Deviation of 1.87. BridgeBio Pharma technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.BridgeBio Pharma Price Movement Analysis
java.lang.NullPointerException: Cannot invoke "java.lang.Number.intValue()" because the return value of "sun.invoke.util.ValueConversions.primitiveConversion(sun.invoke.util.Wrapper, Object, boolean)" is null. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. BridgeBio Pharma middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for BridgeBio Pharma. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
BridgeBio Pharma Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific BridgeBio Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on BridgeBio Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases BridgeBio Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
BridgeBio Pharma Outstanding Bonds
BridgeBio Pharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. BridgeBio Pharma uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most BridgeBio bonds can be classified according to their maturity, which is the date when BridgeBio Pharma has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
BridgeBio Pharma Predictive Daily Indicators
BridgeBio Pharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of BridgeBio Pharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 108592.0 | |||
| Daily Balance Of Power | 0.2353 | |||
| Rate Of Daily Change | 1.01 | |||
| Day Median Price | 75.06 | |||
| Day Typical Price | 75.32 | |||
| Price Action Indicator | 1.09 | |||
| Period Momentum Indicator | 0.6 |
BridgeBio Pharma Corporate Filings
13A | 17th of February 2026 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
8K | 12th of February 2026 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 21st of January 2026 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 12th of January 2026 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 16th of December 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 10th of December 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 8th of December 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 24th of November 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
BridgeBio Pharma Forecast Models
BridgeBio Pharma's time-series forecasting models are one of many BridgeBio Pharma's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary BridgeBio Pharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.BridgeBio Pharma Bond Ratings
BridgeBio Pharma financial ratings play a critical role in determining how much BridgeBio Pharma have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for BridgeBio Pharma's borrowing costs.| Piotroski F Score | 5 | Healthy | View |
| Beneish M Score | (2.68) | Unlikely Manipulator | View |
BridgeBio Pharma Debt to Cash Allocation
As BridgeBio Pharma follows its natural business cycle, the capital allocation decisions will not magically go away. BridgeBio Pharma's decision-makers have to determine if most of the cash flows will be poured back into or reinvested in the business, reserved for other projects beyond operational needs, or paid back to stakeholders and investors.
BridgeBio Pharma currently holds 1.73 B in liabilities with Debt to Equity (D/E) ratio of 4.61, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. BridgeBio Pharma has a current ratio of 5.35, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about BridgeBio Pharma's use of debt, we should always consider it together with its cash and equity.BridgeBio Pharma Total Assets Over Time
BridgeBio Pharma Assets Financed by Debt
The debt-to-assets ratio shows the degree to which BridgeBio Pharma uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.BridgeBio Pharma Debt Ratio | 120.0 |
BridgeBio Pharma Corporate Bonds Issued
BridgeBio Pharma issues bonds to finance its operations. Corporate bonds make up one of the most significant components of the U.S. bond market and are considered the world's largest securities market. BridgeBio Pharma uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt.
BridgeBio Short Long Term Debt Total
Short Long Term Debt Total |
|
About BridgeBio Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how BridgeBio Pharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling BridgeBio shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as BridgeBio Pharma. By using and applying BridgeBio Stock analysis, traders can create a robust methodology for identifying BridgeBio entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (2.81) | (2.95) | |
| Operating Profit Margin | (3.07) | (3.23) | |
| Net Loss | (2.78) | (2.92) | |
| Gross Profit Margin | 1.13 | 1.00 |
Current BridgeBio Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. BridgeBio analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. BridgeBio analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Consensus | # of Analysts | |
| 98.3 | Strong Buy | 19 | Odds |
Most BridgeBio analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand BridgeBio stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of BridgeBio Pharma, talking to its executives and customers, or listening to BridgeBio conference calls.
BridgeBio Stock Analysis Indicators
BridgeBio Pharma stock analysis indicators help investors evaluate how BridgeBio Pharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading BridgeBio Pharma shares will generate the highest return on investment. By understating and applying BridgeBio Pharma stock analysis, traders can identify BridgeBio Pharma position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 394.7 M | |
| Long Term Debt | 1.7 B | |
| Common Stock Shares Outstanding | 186.1 M | |
| Total Stockholder Equity | -1.5 B | |
| Total Cashflows From Investing Activities | 60.8 M | |
| Tax Provision | 1.2 M | |
| Property Plant And Equipment Net | 12.8 M | |
| Cash And Short Term Investments | 681.1 M | |
| Cash | 681.1 M | |
| Accounts Payable | 9.6 M | |
| Net Debt | 1 B | |
| 50 Day M A | 75.4248 | |
| Total Current Liabilities | 154.4 M | |
| Other Operating Expenses | 814.9 M | |
| Non Current Assets Total | 198.6 M | |
| Non Currrent Assets Other | 18.2 M | |
| Stock Based Compensation | 95.8 M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BridgeBio Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in BridgeBio Stock, please use our How to Invest in BridgeBio Pharma guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Will Biotechnology sector continue expanding? Could BridgeBio diversify its offerings? Factors like these will boost the valuation of BridgeBio Pharma. Projected growth potential of BridgeBio fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every BridgeBio Pharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (4.21) | Revenue Per Share | Quarterly Revenue Growth 43.18 | Return On Assets | Return On Equity |
BridgeBio Pharma's market price often diverges from its book value, the accounting figure shown on BridgeBio's balance sheet. Smart investors calculate BridgeBio Pharma's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since BridgeBio Pharma's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between BridgeBio Pharma's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding BridgeBio Pharma should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, BridgeBio Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.